AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)
45.85
-0.45 (-0.97%)
At close: Dec 5, 2025
AnnJi Pharmaceutical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Cash & Equivalents | 427.55 | 629.04 | 597.86 | 267.9 | 391.41 |
| Short-Term Investments | 78 | 76 | 274 | - | - |
| Trading Asset Securities | - | 0.97 | 5.51 | - | - |
| Cash & Short-Term Investments | 505.55 | 706.01 | 877.37 | 267.9 | 391.41 |
| Cash Growth | -36.94% | -19.53% | 227.50% | -31.55% | - |
| Accounts Receivable | 0.07 | 0.15 | - | 0.09 | - |
| Other Receivables | 2.35 | 1.03 | 3.92 | 12.49 | 10.51 |
| Receivables | 2.42 | 1.17 | 3.92 | 12.58 | 10.51 |
| Inventory | 27.42 | 27.42 | - | 4.89 | 5.31 |
| Prepaid Expenses | 7.58 | 9.2 | 37.54 | 20.14 | 4.95 |
| Total Current Assets | 542.96 | 743.8 | 918.82 | 305.51 | 412.18 |
| Property, Plant & Equipment | 71.51 | 76.4 | 82.08 | 6.73 | 11.18 |
| Long-Term Investments | 83.26 | 79.2 | 69.78 | 59.4 | 39.6 |
| Other Intangible Assets | 84 | 100.6 | 134.57 | 168.75 | 202.74 |
| Other Long-Term Assets | 2 | 2 | 2.74 | 0.84 | 0.84 |
| Total Assets | 783.74 | 1,002 | 1,208 | 541.23 | 666.54 |
| Accounts Payable | - | 0.12 | - | - | - |
| Accrued Expenses | 37.01 | 48.39 | 48.09 | 27 | 11.7 |
| Current Portion of Leases | 6.07 | 5.98 | 5.8 | - | 2.79 |
| Current Income Taxes Payable | 36.34 | 40.66 | 38.08 | - | - |
| Current Unearned Revenue | - | 192.73 | 126.09 | 1.6 | - |
| Other Current Liabilities | 29.36 | 2.67 | 9.55 | 2.12 | 1.76 |
| Total Current Liabilities | 108.78 | 290.54 | 227.6 | 30.72 | 16.25 |
| Long-Term Leases | 46.3 | 49.36 | 55.34 | - | - |
| Other Long-Term Liabilities | 118.4 | - | - | - | 0.16 |
| Total Liabilities | 273.48 | 339.9 | 282.94 | 30.72 | 16.41 |
| Common Stock | 938.82 | 936.92 | 908.61 | 658.76 | 623.76 |
| Additional Paid-In Capital | 962.55 | 961.07 | 909.67 | 426.15 | 384.49 |
| Retained Earnings | -1,459 | -1,300 | -946.02 | -616.8 | -380.15 |
| Comprehensive Income & Other | 68.08 | 64.11 | 52.78 | 42.4 | 22.03 |
| Shareholders' Equity | 510.25 | 662.1 | 925.04 | 510.51 | 650.13 |
| Total Liabilities & Equity | 783.74 | 1,002 | 1,208 | 541.23 | 666.54 |
| Total Debt | 52.37 | 55.34 | 61.13 | - | 2.79 |
| Net Cash (Debt) | 453.18 | 650.67 | 816.24 | 267.9 | 388.62 |
| Net Cash Growth | -39.04% | -20.28% | 204.68% | -31.06% | - |
| Net Cash Per Share | 4.84 | 7.00 | 10.55 | 4.08 | 8.60 |
| Filing Date Shares Outstanding | 93.88 | 93.69 | 90.86 | 65.88 | 45.2 |
| Total Common Shares Outstanding | 93.88 | 93.69 | 90.86 | 65.88 | 45.2 |
| Working Capital | 434.18 | 453.26 | 691.22 | 274.79 | 395.93 |
| Book Value Per Share | 5.44 | 7.07 | 10.18 | 7.75 | 14.38 |
| Tangible Book Value | 426.25 | 561.5 | 790.47 | 341.76 | 447.39 |
| Tangible Book Value Per Share | 4.54 | 5.99 | 8.70 | 5.19 | 9.90 |
| Machinery | 34.12 | 33.77 | 35.05 | 36.36 | 36.24 |
| Construction In Progress | - | - | 8.03 | - | - |
| Leasehold Improvements | 17.01 | 16.94 | 7.58 | 4.28 | 4.28 |
Source: S&P Capital IQ. Standard template. Financial Sources.